Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$10.36B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  AMPH
Amphastar Pharmaceuticals
AMPH
91 / 100
High Quality
High Growth
$40.89arrow_drop_up1.79%$0.72

Performance History

Stocklytics logo
Key Stats
Open$40.31
Prev. Close$40.01
EPS2.6
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.95B
PE Ratio15.57
LOWHIGH
Day Range39.94
40.75
52 Week Range35.62
67.66
Ratios
P/B Ratio2.98
Revenue$644.39M
Operating M. %30.31%
Earnings$137.54M
Earnings Growth %50.51%
EBITDA Margin %36.89%
ROE %23.55%
EPS2.6

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

91vs 54. Market Avg.

All Score 91 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

AMPHMARKET
Value5339
Quality8640
Ownership3817
Growth8246
Dividends-38
check_circle

Amphastar Pharmaceuticals 's Price growth average in the last 3 years of 39.88% is great compared to market average of 5.56%. This indicates AMPH could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$735.66
24H (%)arrow_drop_up1.28%
24H ($)$9.35
MARKET CAP$690.55B
PRICE$495.10
24H (%)arrow_drop_down1.20%
24H ($)-$6.03
MARKET CAP$462.00B
PRICE$149.80
24H (%)arrow_drop_up1.27%
24H ($)$1.89
MARKET CAP$356.43B
PRICE$127.49
24H (%)arrow_drop_up1.35%
24H ($)$1.71
MARKET CAP$318.60B

About Amphastar Pharmaceuticals (AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
CEO
Dr. Yongfeng Zhang Ph.D.
Headquarters
Rancho Cucamonga
Employees
1615
Exchange
NASDAQ
add Amphastar Pharmaceuticals  to watchlist

Keep an eye on Amphastar Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Amphastar Pharmaceuticals 's (AMPH) price per share?

The current price per share for Amphastar Pharmaceuticals (AMPH) is $40.22. The stock has seen a price change of $0.46 recently, indicating a 1.15% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Amphastar Pharmaceuticals (AMPH)?

For Amphastar Pharmaceuticals (AMPH), the 52-week high is $67.66, which is 67.19% from the current price. The 52-week low is $35.62, the current price is 13.62% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Amphastar Pharmaceuticals (AMPH) a growth stock?

Amphastar Pharmaceuticals (AMPH) has shown an average price growth of 39.88% over the past three years. It has received a score of 90 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Amphastar Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Amphastar Pharmaceuticals (AMPH) stock price performance year to date (YTD)?

As of the latest data, Amphastar Pharmaceuticals (AMPH) has a year-to-date price change of -35.03%. Over the past month, the stock has experienced a price change of -7.37%. Over the last three months, the change has been -27.63%. Over the past six months, the figure is -9.5%. Looking at a longer horizon, the five-year price change stands at 97.9%.

help
Is Amphastar Pharmaceuticals (AMPH) a profitable company?

Amphastar Pharmaceuticals (AMPH) has a net income of $137.54M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 53.38% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 30.31% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $644.4M, with a revenue growth rate of 29.14%, providing insight into the company's sales performance and growth. The gross profit is $343.97M. Operating income is noted at $199.69M. Furthermore, the EBITDA is $240.29M.

help
What is the market capitalization of Amphastar Pharmaceuticals (AMPH)?

Amphastar Pharmaceuticals (AMPH) has a market capitalization of $1.96B. The average daily trading volume is 352.76K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.